ADVFN
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Vivos Inc (QB)

Vivos Inc (QB) (RDGL)

0.1219
-0.0028
(-2.25%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
0.1219
Bid
0.1191
Ask
0.1238
Volume
474,880
0.1151 Day's Range 0.1243
0.0611 52 Week Range 0.25
Market Cap
Previous Close
0.1247
Open
0.121
Last Trade
19
@
0.12
Last Trade Time
Financial Volume
$ 57,186
VWAP
0.120421
Average Volume (3m)
736,170
Shares Outstanding
453,512,228
Dividend Yield
-
PE Ratio
-18.75
Earnings Per Share (EPS)
-0.01
Revenue
28k
Net Profit
-2.91M

About Vivos Inc (QB)

Vivos Inc, developed an yttrium-90 brachytherapy device to combat cancer in humans and animals. Testing at Washington State University, the University of Missouri and our pilot veterinary clinic has verified the safety to the patient, the therapist and the family members. IsoPet is commercially avai... Vivos Inc, developed an yttrium-90 brachytherapy device to combat cancer in humans and animals. Testing at Washington State University, the University of Missouri and our pilot veterinary clinic has verified the safety to the patient, the therapist and the family members. IsoPet is commercially available for animal therapy and can deliver very high doses to solid tumors with a single same day therapy. Pre-clinical testing is in progress to generate key data for an Investigational Devise Exemption to the FDA to begin human clinical trials. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
-
Vivos Inc (QB) is listed in the Surgical,med Instr,apparatus sector of the OTCMarkets with ticker RDGL. The last closing price for Vivos (QB) was $0.12. Over the last year, Vivos (QB) shares have traded in a share price range of $ 0.0611 to $ 0.25.

Vivos (QB) currently has 453,512,228 shares outstanding. The market capitalization of Vivos (QB) is $56.55 million. Vivos (QB) has a price to earnings ratio (PE ratio) of -18.75.

RDGL Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.00181.49875104080.12010.140.1146305250.12767096CS
4-0.0081-6.230769230770.130.140.11174874890.12713796CS
12-0.0014-1.135442011350.12330.16570.08547361700.12415679CS
26-0.0101-7.651515151520.1320.17390.08548881370.12779628CS
52-0.1232-50.26519787840.24510.250.061111311080.12815976CS
1560.042453.33333333330.07950.2550.048147050.11055599CS
2600.0879258.5294117650.0340.310.0187511341520.10563828CS

RDGL - Frequently Asked Questions (FAQ)

What is the current Vivos (QB) share price?
The current share price of Vivos (QB) is $ 0.1219
How many Vivos (QB) shares are in issue?
Vivos (QB) has 453,512,228 shares in issue
What is the market cap of Vivos (QB)?
The market capitalisation of Vivos (QB) is USD 56.55M
What is the 1 year trading range for Vivos (QB) share price?
Vivos (QB) has traded in the range of $ 0.0611 to $ 0.25 during the past year
What is the PE ratio of Vivos (QB)?
The price to earnings ratio of Vivos (QB) is -18.75
What is the cash to sales ratio of Vivos (QB)?
The cash to sales ratio of Vivos (QB) is 1.2k
What is the reporting currency for Vivos (QB)?
Vivos (QB) reports financial results in USD
What is the latest annual turnover for Vivos (QB)?
The latest annual turnover of Vivos (QB) is USD 28k
What is the latest annual profit for Vivos (QB)?
The latest annual profit of Vivos (QB) is USD -2.91M
What is the registered address of Vivos (QB)?
The registered address for Vivos (QB) is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Vivos (QB) website address?
The website address for Vivos (QB) is www.radiogel.com
Which industry sector does Vivos (QB) operate in?
Vivos (QB) operates in the SURGICAL,MED INSTR,APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GNOLFGenoil Inc (PK)
$ 0.02
(1,999,900.00%)
150k
ATHXQAthersys Inc New (CE)
$ 0.0005
(49,900.00%)
1,000
TRTITranstech Industries Inc (CE)
$ 0.046
(45,900.00%)
71.5k
KDAGFKDA Group Inc (PK)
$ 0.1991
(15,215.38%)
1,000
NOKPFNok Airlines Public Company Ltd (CE)
$ 0.02518
(12,490.00%)
195
AMNIAmerican Noble Gas Inc (CE)
$ 0.000001
(-99.50%)
5.19k
VAXXVaxxinity Inc (CE)
$ 0.0003
(-99.40%)
252
ABMCAmerican Bio Medica Corporation (CE)
$ 0.000001
(-99.00%)
200
PMPGPremier Products Group Inc (CE)
$ 0.000001
(-99.00%)
2.5M
UFABQUnique Fabricating Inc (CE)
$ 0.000001
(-99.00%)
1.4k
AAGHAmerica Great Health (PK)
$ 0.0003
(0.00%)
176.78M
AITXArtificial Intelligence Technology Solutions Inc (PK)
$ 0.00124
(-0.80%)
158.85M
DPLSDarkPulse Inc (PK)
$ 0.00025
(-16.67%)
147.93M
CYBLCyberlux Corp New (PK)
$ 0.0089
(-14.42%)
129.58M
HMBLHUMBL Inc (PK)
$ 0.0003
(0.00%)
121.32M

RDGL Discussion

View Posts
Truthsocial Truthsocial 3 hours ago
Yep lot of people when you include 50000 posts from one poster lol what a fraud
👍️0
nunaka nunaka 3 hours ago
Glad I made my big move during the last anticipatory run up.. This one seems to not be generating much steam.
👍️0
doccjc doccjc 3 hours ago
He's a FUD"ster wannabe.  Not even good at it. Pretty sad 
👍️0
splintered sunlight splintered sunlight 4 hours ago
Apparently a lot of people LMAO.
👍️0
Elonlies Elonlies 6 hours ago
It is not a scam. RDGL is an amazing company.

As a loyal shareholder though, I am pissed off regarding the way they handle IsoPet. Someone once remarked "every time they mention IsoPet
the stock price drops". -
That is an accurate statement 90 percent of the time!!!!!!!!!!!!!!!!!!!!!!!!

Why??? To many discounts-- which can be attributed to two root factors.

1. Dishonest veterinarians milking all the freebies they can obtain.

2. Naive RDGL management that is incapable of cutting the freebie chord.

Translation -- mention a new clinic or conference= Stock price drops lower
👍️0
CatfishHunter CatfishHunter 8 hours ago
The same group, including yourself, would say the same thing if MK was putting out several updates and PRs, calling it a pump. You're a joke.  Move along now 🤣
👍️0
Tiger Money Tiger Money 11 hours ago
How is this scammy?  The Dr in charge would go immediately to jail as they have been clear on their intentions publicly, meaning, they blatantly burried their own grave already if this was a scam.  
👍️0
hotmeat hotmeat 11 hours ago
The only people who still believe Vivos ""smells scammy"" are the stock scammers and the fake arseclowns who know nothing about trading.

Even with all the evidence, ie official FDA acknowledgement, proof of concept via Isopet and an ongoing clinical trial, we still get these planks spewing their garbage.
👍️0
nathanial nathanial 13 hours ago
Volume seems to picking up a tad here.
👍 1
Truthsocial Truthsocial 14 hours ago
RDGL AND ISOPET $12.50 soon IMO
👍️ 3 😎 1 🚀 2
konshe konshe 14 hours ago
See $2 next month.
👍️ 3 😎 1 🚀 1
rogers711 rogers711 14 hours ago
Yes, like I said, 60% chance of success in my opinion... I think it's a pretty solid risk reward but will see. 
👍️ 2
WALLnut WALLnut 14 hours ago
But yet you're still invested here. Seems odd.





$RDGL
👍 1
rogers711 rogers711 14 hours ago
seems the only ppl thinking this is a gem are the people that are long term investors. A lot of outsiders think this smells scammy... seems odd there is no hype/ no price increase going into major news events less than a few weeks away.
👍️0
delerious1 delerious1 14 hours ago
$6.
👍️ 1
Tiger Money Tiger Money 15 hours ago
$5
👍️ 1
hotmeat hotmeat 1 day ago
No real change in the RSI and MFI data for the past 2 weeks but Accumulation has continued its modest upward trend.



👍️ 1
hotmeat hotmeat 1 day ago
What's the going rate these days......$0.05 per post!?!

You stock fraudsters are indeed truly pathetic.
👍️0
nathanial nathanial 1 day ago
But who's counting after 7 years here.
👍️0
splintered sunlight splintered sunlight 1 day ago
You must truly love yourself and not in a healthy way.
👍️0
splintered sunlight splintered sunlight 1 day ago
Yup

What's another 3 weeks after a few years?
👍️ 1
splintered sunlight splintered sunlight 1 day ago
That's what I love about you konshe.

Your optimism!!!!!!!!
👍️0
splintered sunlight splintered sunlight 1 day ago
Maybe RDGL should consider sharing it with the FDA?
👍️0
splintered sunlight splintered sunlight 1 day ago
False pretenses - LMAO
👍️0
splintered sunlight splintered sunlight 1 day ago
You have been for a very long time.

Good for you.
👍️0
splintered sunlight splintered sunlight 1 day ago
Check his and others history - it's been written many times.
👍️0
splintered sunlight splintered sunlight 1 day ago
Seriously?

I haven't been on this board for a long time, because I grew tired of reading this kind of post.

Are you fairly new here?

Been reading that kind of post for years.

I seriously hope it happens.
👍️0
splintered sunlight splintered sunlight 1 day ago
Haven't we bee standing on the doorstep for years now?

Haven't we been prepared to submit what could be the final sprint package that opens the gates to human trials for years now?

Let that sink in.

We have been, potentially weeks, years away form the FDA green lighting the use of RadioGel in human cancer patients.

It hasn't happened.

I hope it does!!!!!!!!!!!!!!!

Is the train in the station?
👍️0
neophyte trader neophyte trader 1 day ago
Or, 12 1/2 trading days (if we don't count the rest of today or July 14th.). July 3rd is early close and the market is closed on the 4th.
👍️ 2
hotmeat hotmeat 1 day ago
Another round of pathetic whinging........do better fraudster!

You post nothing but brainless absurdities.
👍️0
splintered sunlight splintered sunlight 1 day ago
My idiotic premise is still grossly absurd?

LMFAO

I would suggest you huddle with others but you already have - this board - and still don't have an intelligent talking post.

Pathetic
👍️0
nathanial nathanial 1 day ago
By July 14th:

https://x.com/RadioGel/status/1918328552455585815/photo/1

tic toc....tic toc....tic toc....BOOM!!
👍️ 1 😎 1
mikepgator mikepgator 2 days ago
Just a maximum of 3 weeks until FDA submission!!
👍️0
konshe konshe 2 days ago
RDGL will break out 0.13 Today
👍️ 2
WALLnut WALLnut 2 days ago
You're welcome!

Don't forget to share it with friends and family and your favorite media sources.



$RDGL
👍️ 1
Anticipating Anticipating 2 days ago
Thank you sir,
Very informative, and why I’ve chose to ride high on RDGL! Time will tell…
👍️ 2
delerious1 delerious1 3 days ago
I would expect so...if you listen to the interview he sounds open to anything to speed things up. A medical device is still a medication and quite often the medication is already well known, like Y90. So there is lots of data....the gist of the interview he states if there is already data from somewhere else on a study then they will use that data
👍️0
WALLnut WALLnut 3 days ago
Is this the same for Medical Devices?




$RDGK
👍️0
delerious1 delerious1 3 days ago
AI Overview
The new FDA Commissioner, Dr. Marty Makary, has announced a new pilot program called the Commissioner's National Priority Voucher (CNPV) program. This program aims to significantly shorten the drug application review time, potentially reducing it to one to two months for certain drugs that align with the FDA's national priorities. These priorities include addressing health crises, delivering innovative cures, meeting unmet public health needs, and increasing domestic drug manufacturing.

Here's a breakdown of the key aspects:
CNPV Program:
The program awards vouchers to companies developing drugs that address the FDA's national priorities, allowing for expedited review.
Review Time:
Qualifying drugs could see their review time slashed from the typical 10-12 months to just one or two months.
National Priorities:
The program focuses on drugs that address critical health needs, such as a health crisis, deliver innovative cures, address unmet needs, or boost domestic drug manufacturing.
Split-Submission:
The program utilizes a split-submission approach, allowing companies to submit parts of the application, like chemistry, manufacturing, and controls (CMC) data, while clinical trials are still underway.
Voucher Characteristics:
The vouchers are non-transferable and have a two-year expiration date, according to the FDA.
AI Integration:
The FDA is also exploring the use of artificial intelligence, specifically a tool called ELSA, to assist with data curation and retrieval during the review process.
Operational Efficiency:
The program aims to leverage the time spent during clinical trials by allowing for early submission of certain application components.
Focus on Communication:
The program emphasizes enhanced communication and collaboration between drug developers and FDA reviewers.

The program is designed to be a pilot, with the potential for adjustments after the first year. It builds upon existing FDA programs like priority review and breakthrough therapy designation.
👍️ 1
UPMI UPMI 3 days ago
This is a very encouraging thought out post there’s not one thing that anyone could disagree with IMO but as it is we’re still ,and always will be at the mercy of the FDA .We’ll see.
👍️ 1
WALLnut WALLnut 3 days ago
I appreciate that.

We’re at a rare moment in time where the world needs to hear this story — not just investors, but anyone who believes in medical innovation, cancer breakthroughs, and the underdog winning.

Please share it anywhere and everywhere — Facebook, Twitter, family, friends, cancer support communities, investor groups. This isn’t just a ticker — it’s a mission. The more eyes we get on RadioGel, the more pressure builds behind the truth: RDGL is on the verge of something transformational.

Let’s not just watch history unfold — let’s help it happen.

Appreciate you watching from Baltimore. Let’s bring it home.


$RDGL
👍️0
TKS PARTY TKS PARTY 3 days ago
Wallnut, thanks for laying it out there for all to easily understand the magnitude of this moment in time. I would hope we can repost it every day until the next shoe drops. Watching intently from Baltimore.
👍️ 1
hotmeat hotmeat 3 days ago
I see that and I strongly suspect he's not the only one here posting under false pretenses.
👍 1 💯 1
CatfishHunter CatfishHunter 3 days ago
Excellent post brother!! $RDGL long and strong!
👍️ 3
scott135 scott135 4 days ago
Well written! Please post on the board, if possible 
👍️ 4
Rizinup Rizinup 4 days ago
Well written!!
👍️ 3
WALLnut WALLnut 4 days ago
The Tipping Point: RadioGel Is About to Change Everything.


To those watching from the sidelines, wondering if Vivos Inc. (RDGL) and its flagship cancer-fighting technology RadioGel® are worth the investment — let me make this crystal clear:

We are now standing on the doorstep of FDA IDE (Investigational Device Exemption) submission. After years of R&D, animal studies, dosimetry testing, safety validation, radiation delivery modeling, and navigating every regulatory hurdle the FDA has thrown their way, Vivos is preparing to submit what could be the final sprint package that opens the gates to human trials.

Let that sink in:
We are potentially weeks, not years, away from the FDA greenlighting the use of RadioGel in human cancer patients.


---

Why This Matters

RadioGel isn’t just another radiation therapy — it’s a precision-targeted injectable that delivers internal beta radiation directly into solid tumors using a hydrogel matrix. No systemic toxicity. No damage to surrounding healthy tissue. No side effects like you’d see with chemo or external beam radiation. It’s localized, lethal to the tumor, and safe for the patient.

This is the future of interstitial cancer therapy.

Once this treatment enters human trials under the IDE, Vivos isn’t just another speculative biotech — it becomes a first-in-class oncology device company with the ability to address cancers that current technologies cannot treat effectively.


---

For the Fence-Sitters

Yes, it’s been a long road. But biotech breakthroughs don’t happen overnight. What matters is that we’re here now, at the inflection point — when all the science, safety, and data align with regulatory readiness.

And let’s be honest — once that IDE is accepted, everything changes:

Institutional eyes come in

Licensing and partnership talks intensify

Market credibility skyrockets

Valuation? Re-rated overnight


Investors ask, “What’s the upside?” I say: what’s the value of a platform that can be used across multiple tumor types, both in humans and animals, and has already shown strong efficacy in preclinical models?

Add to that the IsoPet® veterinary division, already generating clinical interest and helping animals survive aggressive tumors — validating the core science behind the gel. It’s working.


---

The CEO’s Mission Is Personal

Let’s not forget: CEO Mike Korenko isn’t your typical executive padding a résumé. His goal is personal — he wants to see RadioGel save a child with brain cancer before his time is done. That’s the kind of leadership you cannot buy. That’s a mission you invest in.


---

Final Thought

You don’t get many chances in the market to be early to a disruptive cancer therapy backed by real science, peer-reviewed data, animal success, and now on the verge of human trials.

The train hasn’t left the station yet — but the whistle is blowing.

I’m not just holding. I’m invested in a medical revolution.

– Long and strong on $RDGL
👍️ 15 💯 7
Jimmlu59 Jimmlu59 4 days ago
The mission to Make America Healthy Again (MAHA) includes MABA — Make American Biotech Accelerate.

President Trump showed in his first term what happens when you unlock American science — breakthroughs happen fast.

Now, we’re going to do it again.

We know the power of U.S.…— Secretary Kennedy (@SecKennedy) June 20, 2025
👍️ 4
doccjc doccjc 4 days ago
SS likes to try and stir things up. Not even worth the time . 
👍 3 👍️ 3
hotmeat hotmeat 4 days ago
And yet your idiotic premise is still grossly absurd.

I suggest a huddle with that other jester ol roge so you both can formulate an intelligent (most unlikely) talking point.
👍️0

Your Recent History

Delayed Upgrade Clock